First, our analysis revealed a subset of mutations with tissue-specific prognostic power, including TP53 mutations in breast cancer, RB1 mutations in bladder cancer, and FBXW7 mutations in colorectal cancer. This evidence concerns the gene RB1 and colorectal cancer.